Date published: 2025-10-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

PPT2 Inhibitors

PPT2 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of palmitoyl-protein thioesterase 2 (PPT2), an enzyme involved in the hydrolysis of thioester bonds in palmitoylated proteins. Palmitoylation is a post-translational modification in which fatty acid chains, such as palmitic acid, are added to proteins, influencing their localization, stability, and interaction with membranes. PPT2 plays a critical role in the degradation and recycling of these palmitoylated proteins, particularly in lysosomal pathways where it aids in breaking down protein-lipid complexes. By inhibiting PPT2, these compounds block its enzymatic activity, disrupting the process of depalmitoylation and impacting cellular protein turnover and lipid metabolism.

Research into PPT2 inhibitors offers important insights into how the disruption of palmitoylation and depalmitoylation cycles affects cellular functions, such as protein trafficking, membrane dynamics, and signal transduction. These inhibitors allow scientists to investigate how inhibiting PPT2 influences the fate of palmitoylated proteins within lysosomes, providing a clearer understanding of their roles in cellular homeostasis. PPT2 inhibitors are valuable tools for studying the broader regulatory networks involving lipid-modified proteins and how the processing of these proteins impacts intracellular transport and membrane organization. By using PPT2 inhibitors, researchers can explore the essential role of palmitoylation in various biological processes and gain a deeper understanding of how lipid modification cycles control key aspects of protein function and cellular organization.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Chloroquine affects lysosomal acidity and can impact lysosome-dependent processes, potentially affecting PPT2 expression.

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

Similar to chloroquine, hydroxychloroquine alters lysosomal function, which may influence PPT2 expression.

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$96.00
$250.00
$750.00
$1428.00
280
(6)

Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase, potentially altering lysosomal pH and enzyme expression.

2-Hydroxypropyl-β-cyclodextrin

128446-35-5sc-203461
sc-203461B
sc-203461C
sc-203461A
1 g
100 g
500 g
5 g
$52.00
$620.00
$1950.00
$130.00
8
(1)

This compound disrupts cholesterol homeostasis, potentially affecting membrane-associated proteins and related enzyme expression.

U 18666A

3039-71-2sc-203306
sc-203306A
10 mg
50 mg
$140.00
$500.00
2
(1)

U18666A is a cholesterol transport inhibitor that can induce changes in lysosomal storage, possibly affecting PPT2 expression.

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

As a histone deacetylase inhibitor, Trichostatin A may change chromatin structure and gene expression profiles, including PPT2.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

This DNA methyltransferase inhibitor can affect the methylation status of genes and alter their expression, potentially including PPT2.

Valproic Acid

99-66-1sc-213144
10 g
$85.00
9
(1)

Valproic acid, another histone deacetylase inhibitor, could potentially alter the expression of PPT2 by affecting chromatin structure.

Z-VAD-FMK

187389-52-2sc-3067
500 µg
$74.00
256
(6)

Z-VAD-FMK is a pan-caspase inhibitor that could influence apoptosis pathways and thereby potentially affect lysosomal enzyme levels.

Retinoic Acid, all trans

302-79-4sc-200898
sc-200898A
sc-200898B
sc-200898C
500 mg
5 g
10 g
100 g
$65.00
$319.00
$575.00
$998.00
28
(1)

Retinoic acid affects gene expression through nuclear receptors, which may have downstream effects on lysosomal enzymes such as PPT2.